Effects of naproxcinod on blood pressure in patients with osteoarthritis

American Journal of Cardiology

Volumn 107, Issue 9, 2011, Pages 1338-1345

  White, William B ^a   Schnitzer, Thomas J ^b   Bakris, George L ^c   Frayssinet, Hayet ^d   Duquesroix, Brigitte ^d   Weber, Michael ^e  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NicOx SA   (France)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NAPROXCINOD; NAPROXEN; PLACEBO; RENIN INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; NITRIC OXIDE DONORS; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 79954607068     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.12.046     Document Type: Article

References (19)

1. T.J. Schnitzer, A.J. Kivitz, R.S. Lipetz, N. Sanders, and A. Hee Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee Arthritis Rheum 53 2005 827 837 (Pubitemid 41811122)
2. D.D. Rees, R.M. Palmer, and S. Moncada Role of endothelium-derived nitric oxide in the regulation of blood pressure Proc Natl Acad Sci USA 86 1989 3375 3378 (Pubitemid 19129614)
3. S. Moncada, and E.A. Higgs The discovery of nitric oxide and its role in vascular biology Br J Pharmacol 147 Suppl 1 2006 S193 S201
4. T.J. Schnitzer, A. Kivitz, H. Frayssinet, and B. Duquesroix Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter trial Osteoarthritis Cartilage 18 2010 629 639
5. T.J. Schnitzer, M.C. Hochberg, C.E. Marrero, B. Duquesroix, H. Frayssinet, and M. Beekman Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study Semin Arthritis Rheum 40 2010 285 297
6. C. Baerwald, P. Verdecchia, B. Duquesroix, H. Frayssinet, and T. Ferreira Efficacy, safety and effects of BP of naproxcinod 750 mg b.i.d. compared with placebo and naproxen 500 mg b.i.d. in patients with osteoarthritis of the hip Arthritis Rheum 62 2010 3635 3644
7. T.G. Pickering, J.E. Hall, L.J. Appel, B.E. Falkner, J. Graves, M.N. Hill, D.W. Jones, T. Kurtz, S.G. Sheps, and E.J. Roccella Recommendations for Blood Pressure Measurement in Humans and Experimental Animals Part 1: blood pressure measurement in humans. A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Hypertension 45 2005 142 161 (Pubitemid 40066429)
8. A. Whelton, W.B. White, A.E. Bello, J.A. Puma, J.G. Fort SUCCESS-VII Investigators Effects of celecoxib and rofecoxib on blood pressure and edema in patients >65 years of age with systemic hypertension and osteoarthritis Am J Cardiol 90 2002 959 963 (Pubitemid 35232619)
9. S. Lewington, R. Clarke, N. Qizibash, R. Peto, R. Collins Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913 (Pubitemid 35472129)
10. H.C. Van Houwelingen, L.R. Arends, and T. Stijinen Tutorial in biostatisticsadvanced methods in meta-analysis: multivariate approach and meta-regression Stat Med 21 2002 589 624 (Pubitemid 34141379)
11. M.N. Muscara, W. McKnight, P. Del Soldato, and J.L. Wallace Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat Life Sci 62 1998 235 240 (Pubitemid 28177436)
12. J. Karlsson, A. Pivodic, D. Aguirre, and T.J. Schnitzer Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee J Rheumatol 36 2009 1290 1297
13. W.B. White, T.J. Schnitzer, R. Fleming, B. Duquesroix, and M. Beekman Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis Am J Cardiol 104 2009 840 845
14. W.B. White Cardiovascular effects of the cyclooxygenase inhibitors Hypertension 49 2007 408 418
15. M. Izhar, T. Alausa, A. Folker, E. Hung, and G.L. Bakris Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics Hypertension 43 2004 574 577
16. W.B. White, J. Kent, A. Taylor, K.M. Verburg, J.B. Lefkowith, and A. Whelton Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors Hypertension 39 2002 929 934 (Pubitemid 34437552)
17. T.M. MacDonald, J.Y. Reginster, T.W. Littlejohn, D. Richard, K. Lheritier, G. Krammer, and R. Rebuli Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial J Hypertens 26 2008 1695 1702
18. N.H. McInnis, G. Fodor, M.M. Lum-Kwong, and F.H. Leenan Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ONBP) Am J Hypertens 21 2008 1210 1215
19. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G.T. McInnes, L. Mitchell, F. Plat, A. Schork, B. Smith, A. Zanchetti VALUE Trial Group Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 19 2004 2002 2031